Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcomaThe European Organisation for Research and Treatment of Cancer- Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study

British Journal of Cancer

Volumn 104, Issue 10, 2011, Pages 1544-1550

  Penel, N ^a,b   Glabbeke, M V ^b   Mathoulin Pelissier, S ^c   Judson, I ^d   Sleijfer, S ^e   Bui, B ^c   Schoffski, P ^f   Ouali, M ^b   Marreaud, S ^b   Brouste, V ^c   Duhamel, A ^g   Hohenberger, P ^h   Blay, J Y ⁱ  

^a CENTRE OSCAR LAMBRET   (France)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUT BERGONIÉ   (France)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e Integraal Kankercentrum Rotterdam   (Netherlands)

^f Leuven Cancer Institute   (Belgium)

^g UNIV LILLE   (France)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITÉ LYON 1   (France)

Author keywords

early death; prediction; soft tissue sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ALGORITHM; ANGIOSARCOMA; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEATH; DECISION TREE; EARLY DEATH; FEMALE; FIBROSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER METASTASIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT HISTIOCYTOFIBROMA; NERVE SHEATH TUMOR; OSTEOSARCOMA; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; PROBABILITY TREE ANALYSIS; PROGNOSIS; RHABDOMYOSARCOMA; RISK FACTOR; SCORING SYSTEM; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

EID: 85027948929     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.136     Document Type: Article

References (33)

1. Ambalavanan N, Carlo WA, Shankara S, Bann CM, Emrich SL, Higgins RD, Tyson JE, O'Shea TM, Laptook AR, Ehrenkranz RA, Donovan EF, Walsh MC, Goldberg RN, Das A, National Institute of Child Health and Human Development Neonatal Research Network (2006) Predicting outcomes of neonates diagnosed with hypoxemic-ischemic encephalopathy. Pediatrics 118: 2084-2093 (Pubitemid 46393692)
2. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11: 1276-1285 (Pubitemid 23199130)
3. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634-1639 (Pubitemid 34081505)
4. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27: 2692-2696
5. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2008) Clinical outcome and prognosis factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98: 1029-1033 (Pubitemid 351399798)
6. Barton CA, McKenzie DP, Walters EH, Abramson MJ, Victorian Asthma Mortality Study Group (2005) Interactions between psychosocial problems and management of asthma: who is at risk of dying? J Asthma 42: 249-256 (Pubitemid 40967716)
7. Benjamin RS (1987) Grade 3 nausea, vomiting, and myelosuppression or progressive sarcoma? J Clin Oncol 5: 833-835 (Pubitemid 17119985)
8. Blay JY, Van Glabbeke M, Verweij J, Van Oosterom AT, Le Cense A, Oosterhuis JW, Judson I, Nielsen OS (2003) Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39: 64-69 (Pubitemid 36005426)
9. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP (1987) Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5: 840-850 (Pubitemid 17119988)
10. Bui BN, Chevreau C, Penel N, Bay JO, Coindre JM, Mathoulin-Pelissier S, Ray-Coquard I, Italiano A, Genéve J, Blay JY, The PALSAR 02 Clinical Trial Group (2009) Consolidation with chemotherapy intensification in advanced, metastatic soft tissue sarcoma (STS) of adults. A FNCLCC-French Sarcoma Group phase II multicentric study. J Clin Oncol 27: Abstract 10505
11. Chan F, Cheing G, Chan JYC, Rosenthal DA, Chronister J (2006) Predicting employment outcomes of rehabilitation clients with orthopedic disabilities: a CHAID analysis. Disabil Rehabil 28: 257-270
12. Christakis NA, Lemont EB (2000) Extent and determinants of error in doctors prognoses in terminally ill patients: prospective cohort study. BMJ 320: 469-472 (Pubitemid 30173113)
13. Clark MA, Fischer C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353: 701-711 (Pubitemid 41175678)
14. Clément-Duchêne C, Carnin C, Guillemin F, Martinet Y (2010) How accurate are physicians in the prediction of patient survival in advanced lung cancers? Oncologist 15: 782-789
15. Courville XF, Koval KJ, Carney BT, Spratt KF (2009) Early prediction of posttraumatic in-hospital mortality in pediatric patients. J Pediatr Orthop 29: 439-444
16. Evans C, McCarthy M (1985) Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1: 1204-1206 (Pubitemid 15083681)
17. Fayette J, Penel N, Chevreau C, Blay JY, Cupissol D, Thyss A, Guillemet C, Rios M, Rolland F, Fargeot P, Bay JO, Mathoulin-Pelissier S, Coindre JM, Bui-Nguyen B (2009) Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs 27: 482-489
18. Ferté C, Penel N, Bonneterre J, Adenis A (2010) Individual life-expectancy estimation using validated prognostic scores for patients cancer of unknown primary. Oncology 78: 87-93
19. Geraci JM, Tsang W, Valdres RV, Escalante CP (2006) Progressive disease in patients with cancer presenting to an emergency room with acute symptoms predicts short-term mortality. Supp Care Cancer 14: 1038-1045 (Pubitemid 44451309)
20. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fischer C, Judson I (2008) Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma. Retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112: 1585-1591 (Pubitemid 351441172)
21. Kelly L, White S, Stone PC (2007) The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study. Ann Oncol 18: 1395-1399 (Pubitemid 47307227)
22. Linden A (2006) Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristics (ROC) analysis. J Eval Clin Pract 12: 132-139 (Pubitemid 43384609)
23. Maltoni M, Nanni O, Innocenti MP, Maltoni M, Nanni O, Derni S, Innocenti MP, Fabbri L, Riva N, Maltoni R, Amadori D (1994) Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. Eur J Cancer 30A: 764-766 (Pubitemid 24217330)
24. Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM (2009) Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish Group for Research on Sarcoma. J Clin Oncol 27: 1893-1898
25. Melchior LA, Huba GJ, Gallagher T, Jean-Louis E, McDonald SS, Smereck GA, German VF, Brown VB, Panter AT (2001) Unmet needs in groups of traditionally underserved individuals with HIV/AIDS: empirical models. Home Health Care Serv Q 19: 29-51
26. Parkes CM (1972) Accuracy of prediction of survival in later stages of cancer. Br Med J 2: 29-31
27. Penel N, Vanseymortier M, Bonneterre ME, Clisant S, Dansin E, Vendel Y, Beuscart R, Bonneterre J (2008) Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 26: 53-58
28. Penel N, Négrier S, Ray-Coquard I, Ferté C, Devos P, Hollebecque A, Sawyer MB, Adenis A, Séve P (2009) Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLOS One 4: e6483
29. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. Cancer Res 69: 5383-5391
30. Sessa C, Roggero E, Pampallona S, Regazzoni S, Ghielmini M, Lang M, Marx B, Neuenschwander H, Pagani O, Vasilievic V, Cavalli F (1996) The 3 last months of life cancer patients: medical aspects and role of home-care services in southern Switzerland. Support Care Cancer 4: 180-183
31. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979-985 (Pubitemid 24161844)
32. Sleijfer S, Seynaeve C, Verweij J (2005) Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 10: 833-841 (Pubitemid 43152701)
33. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17: 150-157 (Pubitemid 29022388)